Download Curriculum Vitae

Dr. Tamminga holds the Stanton Sharp Distinguished Chair in Psychiatry at the University of Texas Southwestern Medical School and is the Chairman of the Department of Psychiatry and the Chief, Translational Research in Psychosis at UT Southwestern. She received her M.D. degree from Vanderbilt University and completed residency training in psychiatry at the University of Chicago. She served on the University of Chicago faculty from 1975 to 1979 and moved to the National Institute of Neurological Disorders and Stroke (NINDS) for training in Neurology in 1978. After joining the faculty at the University of Maryland Medical School in 1979, she practiced research, clinical care, and teaching there until joining the faculty at UT Southwestern Medical School in 2003.

Dr. Tamminga has been active in governing boards in the United States. She has been a member of the National Institute of Mental Health (NIMH) National Advisory Board and served on the Board of Scientific Counselors of the NIMH and the National Institute of Drug Abuse, as Council Member and President of the American College of Neuropsychopharmacology, as a Member and Chair of the Psychopharmacological Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA), as well as Consultant for the Orphan Products Development Review Group, FDA. She is a member of the Advisory Board of the Brain and Behavioral Research Foundation (NARSAD) and a member on several of their committees. She has been a Deputy Editor of the American Journal of Psychiatry and on the editorial board of several other journals in the field. Dr. Tamminga was elected to the National Academies of Medicine, then the Institute of Medicine (IOM), in 1998 and has served on several IOM committees in that capacity.

The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness. She evaluates the function of the living human brain in individuals with and without schizophrenia, using brain imaging techniques. Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness. Her ultimate goal is to base novel pharmacologies for psychosis and memory dysfunction on these observations and to use the altered in vivo imaging and postmortem molecular changes as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals.


Medical School
Vanderbilt University Hospital (1971)
Blodgett Memorial Medical Center (1972), Internal Medicine
University of Chicago Hospitals (1975), Psychiatry

Research Interest

  • Human Brain Imaging
  • Human Translational Neuroscience
  • Postmortem Brain Research
  • Schizophrenia Research


Featured Publications LegendFeatured Publications

Honors & Awards

  • Flynn Award
    Yale University Department of Psychiatry (2011)
  • Kempf Award, American Psychiatric Society
    This award recognizes a senior researcher who has made a significant contribution to research on the causes and treatment of schizophrenia as both a researcher and a mentor. (2011)
  • Leiber Award for Schizophrenia Research
    The Lieber Prize for Schizophrenia Research is given in recognition of a research scientist who has made distinguished contributions to the understanding of schizophrenia. (2011)
  • Arvid Carlsson Medal Award
  • Research Lecturer of the Year
    University of Maryland, School of Medicine (2001)

Professional Associations/Affiliations

  • Co-Founder and Organizer, International Congress on Schizophrenia Research
  • Deputy Editor, American Journal of Psychiatry
  • Institute of Medicine, National Academy of Sciences
  • NARSAD Scientific Council Member, currently Executive Committee
  • Stanley Foundation Advisory Board